1、 1.Constant currencies(cc),core results and free cash flow are non-IFRS measures.An explanation of non-IFRS measures can be found on page 42 of the Condensed Interim Financial Report.Unless otherwise noted,all growth rates in this Release refer to same period in prior year.2.Please see detailed guid

2、ance assumptions on page 7.Novartis International AG CH-4002 Basel Switzerland https:/ https:/ FINANCIAL RESULTS|FINANZERGEBNISSE Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3;reaffirms FY 2025 guidance Ad hoc announcement pursuant to Art.53 LR Q3

3、 net sales grew+7%(cc1,+8%USD)and core operating income1 grew+7%(cc,+6%USD)o Sales growth was driven by continued strong execution on priority brands including Kisqali(+68%cc),Kesimpta(+44%cc),Pluvicto(+45%cc)and Scemblix(+95%cc)o Core operating income margin1 was stable(cc)at 39.3%despite increasin

4、g generic impact Q3 operating income grew+27%(cc,+24%USD);net income rose+25%(cc,+23%USD)Q3 core EPS1 grew+10%(cc,+9%USD)to USD 2.25 Q3 free cash flow1 was USD 6.2 billion(+4%USD)driven by higher net cash flows from operating activities Strong nine months performance with net sales up+11%(cc,+11%USD

5、)and core operating income up+18%(cc,+16%USD)Q3 selected innovation milestones:o Rhapsido FDA approval as the only oral,targeted BTK inhibitor for CSU o Ianalumab positive replicate Phase III readouts in Sjogrens disease o Pluvicto positive Phase III PSMAddition data at ESMO o Scemblix positive CHMP

6、 opinion for all lines of CML treatment o Cosentyx positive Phase III readout in PMR o Fabhalta positive Phase III eGFR readout in IgA nephropathy Full-year 2025 guidance2 reaffirmed o Sales expected to grow high single-digit o Core operating income expected to grow low-teens Basel,October 28,2025 C